Get started

CYTK

EXCLUSIVE EWTX 350% BUY/HOLD techs/fundies with catalyst🔸Let's review EWTX daily price chart. Strong V-shape recovery in progress. YTD gains at 218% off the lows, which is an EXCELLENT indicator of the overall health of the stock. Trading 5% below 52 week high. 🔸Based on technicals, I envision a C*H breakout in 2025 after we hit overhead resistance we can expect a pullback in order to fill the massive liquidity gap left behind near 22 USD. currently stock is trading near 35 handle and expecting limited upside going forward into Q4 2024. Market cap is hovering near 3 Bln USD so it's not a penny stock and also market cap is not inflated. 🔸CYTK competitor stock chart on the right, similarly priced and also same line of business as EWTX. Trading at 53 USD now previously maxed out at 100 USD, current CYTK market cap is 6 Bln USD, at the peak market cap was 12 Bln USD. So potentially EWTX can do x4 from current levels in order to hit CYTK max market cap. this means x4 stock prices for EWTX from current levels, so it's 34 x 4 = 136 USD max projected stock price. 🔸My PT for EWTX in 2025 is 100 USD, based on the technicals and fundamentals. Recommended strategy bulls: wait for pullback/rejection from overhead resistance and be ready to BUY/HOLD once we do a COMPLETE gap fill of the liquidity gap near 22 USD. Target is 100 USD, 350%+ upside from entry price. Good luck traders! 🔸Below supplementary fundies info on EWTX / some info on the positive catalysts, you can dig deeper if required. 🔸Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious muscle diseases, particularly rare neuromuscular and cardiac disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company leverages its deep expertise in muscle biology to create innovative therapies aimed at unmet medical needs. 🔸Their lead product candidate, EDG-5506, is being developed to treat Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). This small molecule is designed to prevent contraction-induced muscle damage, offering potential benefits in improving muscle function for patients with ystrophinopathies. The drug is currently in Phase 2 trials, and has shown promising results in reducing muscle damage biomarkers​ ​ 🔸Another key program focuses on EDG-7500, an experimental therapy for hypertrophic cardiomyopathy (HCM). This drug is a selective sarcomere modulator designed to improve cardiac relaxation and contraction. The company initiated Phase 1 trials for EDG-7500 in 2023​. ​ 🔸Edgewise is dedicated to both advancing scientific research and engaging with patient communities, frequently collaborating with organizations such as the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy 🔸The biotech company tested its drug, EDG-7500, in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy. In this disease, a genetic mutation causes the heart ventricles to thicken. This limits cardiac function and exercise capacity. 🔸After a single dose, patients showed improved blood flow from the left ventricle. But sometimes drugs can do their job too well, suppressing cardiac function — a measure known as reduced left ventricular ejection fraction, or LVEF. But patients didn't show meaningful reductions in LVEF. 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:EWTXLong
by ProjectSyndicate
13
Why Now is the Time to Buy Cytokinetics ($CYTK) Stock In the dynamic landscape of the stock market, investors are constantly on the lookout for hidden gems that offer promising returns. Cytokinetics ( NASDAQ:CYTK ), a biopharmaceutical company dedicated to developing muscle activators, is emerging as a compelling investment opportunity. This Idea delves into the factors that make Cytokinetics an attractive prospect for buyers, exploring the company's innovative pipeline, strategic partnerships, and potential for future growth. 1. Revolutionizing Muscle Biology: Cytokinetics has positioned itself at the forefront of muscle biology research, focusing on developing therapeutics that enhance muscle function and mobility. The company's dedication to addressing unmet medical needs in diseases related to muscle weakness sets it apart in the biopharmaceutical industry. With a robust pipeline featuring novel compounds, Cytokinetics is poised to revolutionize the treatment landscape for various neuromuscular disorders. 2. Omecamtiv Mecarbil - A Potential Game-Changer: At the heart of Cytokinetics' success lies Omecamtiv Mecarbil, a cardiac myosin activator currently in advanced clinical trials. Positive data from earlier stages of development suggest that this drug has the potential to be a game-changer in the treatment of heart failure. As the trials progress, investors are eagerly anticipating further validation of Omecamtiv Mecarbil's efficacy, with successful outcomes likely to drive substantial value for NASDAQ:CYTK shareholders. 3. Strategic Partnerships Fueling Growth: Cytokinetics has strategically forged partnerships with key players in the pharmaceutical industry. Collaborations with global giants, such as Amgen and Astellas, not only provide financial support but also validate the company's innovative approach. These partnerships also enhance Cytokinetics' ability to navigate the complex regulatory landscape, potentially expediting the development and commercialization of its groundbreaking therapies. 4. Addressing Unmet Medical Needs: NASDAQ:CYTK is uniquely positioned to address unmet medical needs in diseases characterized by muscle weakness. The company's research and development efforts target conditions such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and hypertrophic cardiomyopathy (HCM). By addressing these underserved therapeutic areas, Cytokinetics is not only contributing to patient welfare but also opening up significant market opportunities. 5. Financial Stability and Growth Potential: Cytokinetics has demonstrated financial stability, with a strategic allocation of resources to support its research and development initiatives. The company's revenue growth, coupled with prudent financial management, bodes well for investors seeking long-term stability and potential returns. As Cytokinetics advances its pipeline and secures regulatory approvals, the growth potential for NASDAQ:CYTK becomes increasingly promising. Cytokinetics ( NASDAQ:CYTK ) stands on the cusp of transformative success in the biopharmaceutical industry. With a pioneering approach to muscle biology, a promising pipeline, strategic partnerships, and a focus on addressing unmet medical needs, Cytokinetics is capturing the attention of investors seeking opportunities in the healthcare sector. As the company progresses through clinical trials and potential regulatory approvals, NASDAQ:CYTK has the potential to deliver substantial returns to investors who recognize the value of innovation in improving patient outcomes and addressing critical healthcare challenges.
NASDAQ:CYTKLong
by DEXWireNews
New Highs & Levels For CYTKCYTK put in a fresh high today which was rejected HARD almost immediately after. This came after the company announced positive topline results from 2 cohorts in its REDWOOD-HCM Phase 2 clinical trial of CK-3773274 (CK-274). This is the company’s investigational treatment targeting hypertrophic cardiomyopathy. “The combined data from Cohorts 1 and 2 in REDWOOD-HCM met our high expectations for this trial of CK-274 in patients with obstructive HCM, given the observed onset of response to initiation of treatment, magnitude and breadth of response, reversibility of LVEF decreases, and favorable tolerability profile,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. Looks like the 236 fib line - using lows from the major gap down - has been a pivot over the last year or so. CYTK tested that level on July 19th and bounced during the morning session. The big question is can it maintain this as a new support level or is it looking at another breakdown following this huge move? "Thanks to these results, Cytokinetics expressed its anticipation of what its Phase 3 trial could bring to the table. Let’s put this into perspective. CYTK wasn’t any of the penny stocks that broke out last year. However, its valuation was a fraction of what it is today. Last October, CYTK stock was trading around $15 a share; more than 50% less than its value on July 19th. With that, attention is certainly on smaller biotech stocks right now." Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
NASDAQ:CYTK
by PennyStocks101
CYTK, Broadening Wedge Descending (bearish) I found this pattern at tickeron website with the following data: STATUS = Confirmed CURRENT CONFIDENCE = 82% TARGET (EXIT) PRICE = 14.29 USD BREAKOUT (ENTRY) PRICE = 15.34 USD DISTANCE TO TARGET PRICE = 8.46% EMERGED ON = Oct 28, 12:00 PM (EDT) CONFIRMED ON = Oct 28, 03:56 PM (EDT) WITH CONFIDENCE LEVEL = 91% The Broadening Wedge Descending pattern forms when a security price makes lower lows (1, 3, 5) and lower highs (2, 4), forming two downward sloping lines that expand over time (kind of like a pointed down megaphone shape). This pattern may form when large investors spread out their selling over a period of time, and the Breakout can occur in either direction. When the initial selling occurs, other market participants react to falling price and jump on the bandwagon to participate. Then the value investors begin to sell, believing the price has not fallen enough, which spurs the original large investor to resume selling again. Trade idea If price breaks out from the bottom pattern boundary, day traders and swing traders should trade with a DOWN trend. Consider selling the security short or buying a put option at the downward breakout price level. To identify an exit, compute the target price by assessing the difference between the pattern’s lowest high (2) and the breakout level. That is the pattern height. The target price can be calculated by subtracting the pattern height from the downward breakout level, which is the last low touching the bottom line. To limit potential loss when price suddenly goes in the wrong direction, consider placing a stop order to buy back a short position or sell a put option at or above the breakout price.
NASDAQ:CYTKShort
by AlTorress
CYTK, Pennant (bullish pattern)I found this pattern at tickeron website with the following data: STATUS = Confirmed CURRENT CONFIDENCE = 77% TARGET (EXIT) PRICE = 18.60 USD BREAKOUT (ENTRY) PRICE = 16.75 USD DISTANCE TO TARGET PRICE = 14.39% EMERGED ON = Oct 19, 12:00 PM (EDT) CONFIRMED ON = Oct 19, 11:59 AM (EDT) WITH CONFIDENCE LEVEL = 91% The Rising Pennant (or Bullish Pennant) pattern looks like a pennant with a mast. It forms when rising prices experience a consolidation period, and the price moves within a narrow range defined by the converging lines through points (2, ­4) and (3, ­5). After the consolidation, the previous trend resumes. This type of formation happens when anticipation of an uptrend is high, and when the price of a security consolidates within a range. It indicates growing investor interest in a potentially explosive uptrend. Trade idea Once the price breaks out from the top pattern boundary, day traders and swing traders should trade with an UP trend. Consider buying a security or a call option at the breakout. The breakout price level for the Rising Pennant pattern is the last point touching the top line (4). To identify an exit, compute the target price by adding the initial rise between points 1 and 2 to the breakout price. When trading, wait for the confirmation move, which is when the price rises above the breakout level. To limit potential loss when price suddenly goes in the wrong direction, consider placing a stop order to sell at or below the breakout price.
NASDAQ:CYTKLong
by AlTorress
CYTK, MACD Histogram just turned positiveThis is a Bullish indicator signaling CYTK's price could rise from here. Traders may explore going long the stock or buying call options. Tickeron A.I. dvisor identified 44 similar cases where CYTK's MACD histogram became positive, and 42 of them led to successful outcomes. Odds of Success: 90%. Current price $22.85 crossed the support line at $22.88 and is trading between $22.88 support and $22.14 resistance lines. Throughout the month of 08/26/20 - 09/28/20, the price experienced a -7% Downtrend, while the week of 09/21/20 - 09/28/20 shows a +5% Uptrend. Bullish Trend Analysis The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CYTK's RSI Oscillator exited the oversold zone, Tickeron AI shows that in 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%. The Stochastic Indicator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 54 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%. Following a +11.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 263 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 85%. CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. The Aroon Indicator entered an Uptrend today. Tickeron AI shows that in 218 of 252 cases where CYTK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
NASDAQ:CYTKLong
by AlTorress
1
CYTOKINETICS INC - NASDAQ: $CYTK Grinding HigherAfter recapturing its 200 DMA in early Spring (March), shares of CYTOKINETICS INC - NASDAQ;CYTK have been grinding into higher ground as we can observe in the Daily chart above. Additionally, CYTK continues to trade above all of its important moving averages 20/50/200 DMA's, suggestive of a favorable technical posture. Furthermore, when extending out to both the Weekly and Monthly time-frames, CYTK remains in relatively good shape, thus, we have a stock that displays encouraging technical's across multiple time-frames. Moving forward, both investors/traders may want to continue to monitor the action closely, particularly, should CYTK be capable of going topside of the $11.50 figure and perhaps of more importance the $11.95 level, such development would likely trigger its next advance into a primary objective of $13 with a secondary objective in the $16 handle. Thus, investors/traders may want to put CYTK front-and-center on their radars and pay close attention to the levels mentioned above for additional clues/evidence that CYTK is ready to embark on its next major leg.
NASDAQ:CYTK
by InsiderFinancial